Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ:BDTX
Want to see BDTX full AI Analyst Report?
Top Page
Black Diamond Therapeutics
(NASDAQ:BDTX)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.00
▼(-34.64% Downside)
Action:Reiterated
Date:05/23/26
The score is held back primarily by weak and volatile financial performance (TTM losses, $0 TTM revenue, and renewed cash burn) and a technically weak price trend below major moving averages. These negatives are partially offset by a meaningful positive clinical update for silevertinib, while valuation signals are constrained by the company’s loss-making profile and lack of dividend data.
Positive Factors
Precision mutation-targeting platform
A validated platform that targets specific cancer-driving mutations provides a durable competitive advantage: it enables focused patient selection, higher likelihood of response, and the potential to generate multiple indication-specific assets. Over 2–6 months, platform credibility supports partnerships and efficient trial designs that de‑risk later-stage development and create repeatable R&D value.
Negative Factors
Return to cash outflows and weak cash generation
Sustained negative operating and free cash flow signals renewed cash burn that elevates funding risk. Over 2–6 months this increases the likelihood of dilutive financing or the need for partnerships to fund pivotal programs, squeezing holders and constraining the company's ability to independently advance multiple programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Precision mutation-targeting platform
A validated platform that targets specific cancer-driving mutations provides a durable competitive advantage: it enables focused patient selection, higher likelihood of response, and the potential to generate multiple indication-specific assets. Over 2–6 months, platform credibility supports partnerships and efficient trial designs that de‑risk later-stage development and create repeatable R&D value.
Read all positive factors
Black Diamond Therapeutics (BDTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$108.87M
Dividend YieldN/A
Average Volume (3M)1.71M
Price to Earnings (P/E)―
Beta (1Y)2.38
Revenue Growth-100.00%
EPS Growth-1056.82%
CountryUS
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.76
Shares Outstanding57,301,773
10 Day Avg. Volume1,392,831
30 Day Avg. Volume1,709,145
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.23
Price to Sales (P/S)1.97
P/FCF Ratio4.67
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.02K
Enterprise Value/Ebitda-2.85
Forecast
1Y Price Target
$10.25Price Target Upside234.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$7.14M
Black Diamond Therapeutics Business Overview & Revenue Model
Company Description
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is ...
How the Company Makes Money
BDTX makes money primarily through (1) collaboration and partnership revenue and (2) interest and other income on its cash and investment balances; as a clinical-stage biotech, it does not have a broad, recurring product-sales base. Collaboration ...
Black Diamond Therapeutics Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
63
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 70.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -113.00K | 69.67M | 0.00 | -437.00K | 0.00 | 0.00 |
| EBITDA | -40.34M | 20.20M | -78.44M | -86.02M | -92.32M | -126.67M |
| Net Income | -43.21M | 22.37M | -69.68M | -82.44M | -91.17M | -125.60M |
Balance Sheet | ||||||
| Total Assets | 132.92M | 143.01M | 122.64M | 158.57M | 156.25M | 247.68M |
| Cash, Cash Equivalents and Short-Term Investments | 118.26M | 128.65M | 98.58M | 131.40M | 122.81M | 209.79M |
| Total Debt | 17.88M | 15.07M | 22.19M | 25.30M | 28.14M | 28.46M |
| Total Liabilities | 28.62M | 30.80M | 39.35M | 41.83M | 40.56M | 51.78M |
| Stockholders Equity | 104.30M | 112.21M | 83.28M | 116.74M | 115.69M | 195.90M |
Cash Flow | ||||||
| Free Cash Flow | -34.03M | 29.61M | -62.30M | -66.75M | -85.27M | -102.86M |
| Operating Cash Flow | -34.03M | 29.61M | -62.30M | -66.72M | -85.08M | -100.15M |
| Investing Cash Flow | -33.95M | -44.91M | 16.97M | 16.35M | 53.37M | 130.61M |
| Financing Cash Flow | -363.00K | -146.00K | 25.55M | 71.93M | 177.00K | 729.00K |
Black Diamond Therapeutics Technical Analysis
Negative
3.06
Price Trends
2.63
Negative
2.48
Negative
2.92
Negative
Market Momentum
-0.22
Positive
35.43
Neutral
4.68
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDTX, the sentiment is Negative. The current price of 3.06 is above the 20-day moving average (MA) of 2.49, above the 50-day MA of 2.63, and above the 200-day MA of 2.92, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 35.43 is Neutral, neither overbought nor oversold. The STOCH value of 4.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BDTX.
Black Diamond Therapeutics Risk Analysis
Black Diamond Therapeutics disclosed 81 risk factors in its most recent earnings report. Black Diamond Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Black Diamond Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $1.43B | -44.97 | -47.12% | ― | ― | 41.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $108.87M | -2.52 | -36.37% | ― | -100.00% | -1056.82% | |
48 Neutral | $292.05M | -8.31 | -77.09% | ― | ― | -9.22% | |
46 Neutral | $207.25M | -1.75 | -55.97% | ― | -45.50% | -35.63% | |
44 Neutral | $54.39M | -1.15 | -39.76% | ― | ― | 40.85% | |
41 Neutral | $158.72M | -6.04 | 21.05% | ― | ― | 43.38% |
* Healthcare Sector Average
BDTX
Black Diamond Therapeutics
1.90
-0.47
-19.83%
SLS
SELLAS Life Sciences Group
7.68
6.18
412.00%
GALT
Galectin Therapeutics
2.41
1.09
82.58%
VYGR
Voyager Therapeutics
3.43
0.05
1.48%
DMAC
Diamedica Therapeutics
5.42
1.39
34.49%
TIL
Instil Bio
8.02
-28.54
-78.06%
Black Diamond Therapeutics Corporate Events
Business Operations and Strategy
Black Diamond Highlights Positive Phase 2 Silevertinib Lung Cancer Data
Positive
May 22, 2026
On May 21, 2026, Black Diamond Therapeutics reported positive Phase 2 data for silevertinib in treatment‑naïve non‑small cell lung cancer patients with non‑classical EGFR mutations, based on an April 11, 2026 data cutoff. In...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.